Lymphocytic Neoplasm

In this 1991 study the authors included 363 children diagnosed with B-lymphoblastic leukemia (B-ALL). Cytogenetic analysis idenitified a t(9;22) (q34;q11) also known as BCR::ABL1 in 15 cases (4.1%). T… (full text at CIViC)

PMID 1991160 · Fletcher et al., 1991 · Open in CIViC

In this large 2022 landscape study the authors include 2,754 children, adolescents and young adults (AYA) with newly diagnosed B-ALL (n=2,288 cases) or T-ALL (n=466). Median age at diagnosis was 6.4 y… (full text at CIViC)

PMID 36050548 · Brady et al., 2022 · Open in CIViC

In this 1986 study the authors included 329 newly diagnosed patients with B-lymphoblastic leukemia (B-ALL), including 157 children and 172 adults. Cytogenetic analysis detected a t(9;22)(q34;q11) abno… (full text at CIViC)

PMID 3455828 · Bloomfield et al., 1986 · Open in CIViC

In a phase I/II, open-label trial, 570 patients with Philadelphia chromosome–positive CML were enrolled. Patient cohorts included second-line chronic phase (CP) CML (n = 286), third-/fourth-line CP CM… (full text at CIViC)

PMID 24345751 · Kantarjian et al., 2014 · Open in CIViC

In a phase 2, open-label trial, a cohort of 78 patients with BCR-ABL positive ALL received 60 mg/m2 of dasatinib daily for up to 24 months in combination with chemotherapy (AIEOP-BFM ALL 2000 multi-ag… (full text at CIViC)

Open in CIViC

Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with no secondary variants in at least ten bacterial clones generated using perip… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In this phase 1 dose-escalation study, 119 patients with imatinib-resistant, Ph-positive CML or acute lymphoblastic leukemia (ALL) to receive nilotinib orally at doses of 50 mg, 100 mg, 200 mg, 400 mg… (full text at CIViC)

PMID 16775235 · Kantarjian et al., 2006 · Open in CIViC

Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with the E255K secondary variant in 3/12 bacterial clones generated using periphe… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In a retrospective study of 45 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABLfusion positive (Ph+) chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia (ALL) patients, a Ph+… (full text at CIViC)

PMID 17339191 · Soverini et al., 2007 · Open in CIViC

In an in vitro kinase study, the recombinant ABL1 H396P mutant kinase did not demonstrate resistance to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 1 and 1) when compared to wil… (full text at CIViC)

PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC

In a retrospective study of 84 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1 fusion positive (Ph+) chronic myeloid leukemia (in accelerated-phase or with blast crisis) or Ph+ acut… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In this open-label, phase II study, 36 patients with Ph-positive imatinib-resistant or intolerant ALL previously treated with standard induction or consolidation chemotherapy, or imatinib-resistant or… (full text at CIViC)

PMID 17496201 · Ottmann et al., 2007 · Open in CIViC

Bone marrow mononuclear cells (BM MNCs) were isolated from three acute lymphoblastic leukemia patients with the BCR-ABL1 T315I variant who were pretreated with various chemotherapeutics and dasatinib.… (full text at CIViC)

PMID 25686603 · Pemovska et al., 2015 · Open in CIViC

In a retrospective study of 45 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL fusion positive (Ph+) chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia (ALL) patients, pati… (full text at CIViC)

PMID 17339191 · Soverini et al., 2007 · Open in CIViC

Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with Y253H and Y253H/Q252R variants in 9/10 and 1/10 clones, respectively. Clones… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

70 yo with t(8;22)(p11;q11) and BCR::FGFR1 rearrangement presenting as pre-B ALL with complex cytogenetic abnormalities. Flow cytometric analysis at diagnosis showed B cell immunophenotype. BCR-FGFR1 … (full text at CIViC)

PMID 20594995 · Baldazzi et al., 2010 · Open in CIViC

In this study which included 1389 cases of high-risk pediatric B-ALL, 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on the 129… (full text at CIViC)

PMID 28408464 · Reshmi et al., 2017 · Open in CIViC

In this study involving 574 pediatric B-ALL patients (from a Dutch/German cohort), 77 were shown to be Ph-like cases identified by hierarchical clustering of gene expression data. In one male patient … (full text at CIViC)

PMID 27894077 · Boer et al., 2017 · Open in CIViC

A 47-year-old man was diagnosed with pre-B-cell acute lymphoblastic leukemia. FISH and nested PCR revealed the patient had a t(4;22)(q12;11) translocation that created an in-frame BCR-PDGFRA fusion. T… (full text at CIViC)

PMID 12944919 · Trempat et al., 2003 · Open in CIViC

A 39-year-old Chinese man was hospitalized in May 2021 with concerns of thirst and weight loss. Immature B lymphocytes were detected in blood (83.8%) and bone marrow (87%) and FISH showed the absence … (full text at CIViC)

PMID 41143846 · Hua et al., 2024 · Open in CIViC

BIRC3 mutations have been described in MCL in multiple studies

PMID 32160292 · Pararajalingam et al., 2020 · Open in CIViC

BIRC3 mutations were identified in 23 of 919 screened CLLs. They are strongly linked to non-mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for poor outcome.

PMID 24943832 · Baliakas et al., 2015 · Open in CIViC

This study reportedly sequenced 1001 DLBCL tumors using whole exome sequencing. They reported 150 recurrently mutated genes. Some concerns about the validity of the results have been expressed in subs… (full text at CIViC)

PMID 28985567 · Reddy et al., 2017 · Open in CIViC

A preclinical study investigated BTK inhibitor ibrutinib as a potential inhibitor for patients with pre-BCR + B cell acute lymphoblastic leukemia (B-ALL). In validating the significance of BTK and BLK… (full text at CIViC)

PMID 28031181 · Kim et al., 2017 · Open in CIViC

Observed mutated in BL in more than one genomic data set

PMID 31558468 · Panea et al., 2019 · Open in CIViC

This study performed exome sequencing on 55 DLBCL tumor samples and identified several significantly mutated genes including BRAF.

PMID 22343534 · Lohr et al., 2012 · Open in CIViC

In 47 patients with Hairy Cell Leukemia, sequencing discovered a V600E mutation in all 47 of the sequenced patients.

PMID 21663470 · Tiacci et al., 2011 · Open in CIViC

In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type.

PMID 23612012 · Andrulis et al., 2013 · Open in CIViC

In these two phase II studies (Italy and U.S. locations), BRAF V600E-mutant hairy-cell leukemia was treated with vemurafenib at a dose of 960 mg twice daily to investigate its efficacy. The overall re…

This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC)

PMID 21796119 · Morin et al., 2011 · Open in CIViC

This study used a combination of RNA-seq, whole genome and targeted sequencing to identify recurrently mutated genes in follicular and diffuse large B-cell lymphoma. They reported 30 genes that had si… (full text at CIViC)

PMID 21796119 · Morin et al., 2011 · Open in CIViC

The effective cohort in this study was 11 CLL patients who were first treated with ibrutinib and then on progression treated with venetoclax until progression. Patient samples were sequenced before an… (full text at CIViC)

PMID 32232486 · Lucas et al., 2020 · Open in CIViC